Vismodegib

Results: 20



#Item
1article published online: 8 january 2012 | doi: nchembio.765 Oxysterols are allosteric activators of the oncoprotein Smoothened

article published online: 8 january 2012 | doi: nchembio.765 Oxysterols are allosteric activators of the oncoprotein Smoothened

Add to Reading List

Source URL: rohatgi.stanford.edu

Language: English - Date: 2013-02-15 12:38:42
2Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic,1 MR Migden,2 AE Oro,3 L Dirix,4 K Lewis,5 JD Hainsworth,6

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic,1 MR Migden,2 AE Oro,3 L Dirix,4 K Lewis,5 JD Hainsworth,6

Add to Reading List

Source URL: www.curis.com

Language: English - Date: 2014-05-12 19:51:02
3Vismodegib, a Hedgehog Pathway Inhibitor, in Advanced Basal Cell Carcinoma: STEVIE Study Interim Analysis in 300 Patients Jean-Jacques Grob, Rainer Kunstfeld, Brigitte Dréno, Thomas Jouary, Laurent Mortier, Paolo A. Asc

Vismodegib, a Hedgehog Pathway Inhibitor, in Advanced Basal Cell Carcinoma: STEVIE Study Interim Analysis in 300 Patients Jean-Jacques Grob, Rainer Kunstfeld, Brigitte Dréno, Thomas Jouary, Laurent Mortier, Paolo A. Asc

Add to Reading List

Source URL: www.curis.com

Language: English - Date: 2014-05-12 19:51:02
    48579  Efficacy and Safety of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Basal Cell Carcinoma (BCC): ERIVANCE BCC Study Update Aleksandar Sekulic,1 Michael R Migden,2 Anthony E Oro,3 Karl Lewis,4

    8579 Efficacy and Safety of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Basal Cell Carcinoma (BCC): ERIVANCE BCC Study Update Aleksandar Sekulic,1 Michael R Migden,2 Anthony E Oro,3 Karl Lewis,4

    Add to Reading List

    Source URL: www.curis.com

    Language: English - Date: 2014-05-12 19:51:02
      5Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma (aBCC): 18-Month Update of the Pivotal ERIVANCE BCC Study Aleksandar Sekulic,1 Michael R. Migden,2 Nicole Basset-Seguin,3 Claus G

      Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma (aBCC): 18-Month Update of the Pivotal ERIVANCE BCC Study Aleksandar Sekulic,1 Michael R. Migden,2 Nicole Basset-Seguin,3 Claus G

      Add to Reading List

      Source URL: www.curis.com

      Language: English - Date: 2014-05-12 19:51:30
      6Skin tumors develop specific mutations to resist drug, researchers say

      Skin tumors develop specific mutations to resist drug, researchers say

      Add to Reading List

      Source URL: medicalxpress.com

      Language: English - Date: 2015-04-13 14:02:44
      7NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication  VISMODEGIB

      NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication VISMODEGIB

      Add to Reading List

      Source URL: www.england.nhs.uk

      Language: English - Date: 2013-10-02 10:04:37
      8Roche Infographic - Advanced Basal Cell Carcinoma (BCC)

      Roche Infographic - Advanced Basal Cell Carcinoma (BCC)

      Add to Reading List

      Source URL: www.roche.com

      Language: English - Date: 2013-07-12 04:22:31
      9Microsoft Word - Advanced Basal Cell Carcinoma

      Microsoft Word - Advanced Basal Cell Carcinoma

      Add to Reading List

      Source URL: www.roche.com

      Language: English - Date: 2013-07-08 10:50:29
      10Vismodegib Briefing Package: Pediatric ODAC Subcommittee Meeting (1 November 2011)

      Vismodegib Briefing Package: Pediatric ODAC Subcommittee Meeting (1 November 2011)

      Add to Reading List

      Source URL: www.fda.gov

      Language: English